Treatment of metastatic HR+, HER2-Breast Cancer with Abemaciclib Significant Prolongation of progression-free and Overall Survival - also in Subgroups

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：485 / 485
页数：1
相关论文
共 50 条
  • [1] Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Tremblay, Gabriel
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 69 - 78
  • [2] Composite biomarkers for the prediction of progression-free survival with CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer
    Witkiewicz, Agnieszka
    Wang, Jianxin
    Knudsen, Erik
    Levine, Ellis
    O'Connor, Tracey
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [3] Effect of metformin on progression-free survival outcomes in patients with advanced or metastatic HR+, HER2-breast cancer: subgroup analysis of STEPAUT
    Egle, D.
    Marth, C.
    Steger, G.
    Bartsch, R.
    Pfeiler, G.
    Greil, R.
    Helfgott, R.
    Oehler, L.
    Hennebelle, M.
    Gnant, M.
    [J]. BREAST, 2017, 32 : S26 - S27
  • [4] Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/ HER2- metastatic breast cancer?
    Forsythe, Anna
    Chandiwana, David
    Barth, Janina
    Thabane, Marroon
    Baeck, Johan
    Shor, Anastasiya
    Tremblay, Gabriel
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1015 - 1025
  • [5] Dalpiciclib Extends Progression-Free Survival in HR+/HER2-Advanced Breast Cancer
    不详
    [J]. ONCOLOGIST, 2021, 26 : S9 - S10
  • [6] Abemaciclib for the treatment of HR+/HER2- breast cancer
    Exman, Pedro
    Tolaney, Sara M.
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018, 3 (03): : 151 - 161
  • [7] Abemaciclib for Patients with advanced or metastatic HR plus Breast Cancer and HER2-Breast Cancer Benefits in Overall Survival - even in Patients with visceral Metastases
    Ruedesheim, Sabine M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [8] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [9] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    [J]. TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [10] nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
    Hamilton, E. P.
    Cortes, J.
    Ozyilkan, O.
    Chen, S-C.
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Huober, J.
    Chapman, S. C.
    Yang, Z.
    Chen, Y.
    Johnston, E. L.
    Martin, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S348 - S348
12345